Bicyclol mitigates lipopolysaccharide-induced acute lung injury through myeloid differentiation factor 88 inhibition

doi:10.1016/j.taap.2024.116958

科研成果详情

题名	Bicyclol mitigates lipopolysaccharide-induced acute lung injury through myeloid differentiation factor 88 inhibition
作者	Fu, Lili1; Cheng, Linting1; Lu, Junliang1; Ye, Qianru1; Shu, Cong1; Sun, Chuchu 1; Liu, Zhiguo1; Liang, Guang 2; Zhao, Weixin1,3
发表日期	2024-05-11
发表期刊	Toxicology and applied pharmacology 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Acute Lung Injury Anti-Inflammatory Bicyclol Cytokines Lipopolysaccharide MyD88
其他关键词	SIGNAL-TRANSDUCTION ; RECEPTORS
摘要	Acute lung injury (ALI) remains a significant clinical challenge due to the absence of effective treatment alternatives. This study presents a new method that employs a screening platform focusing on MyD88 affinity, anti-inflammatory properties, and toxicity. This platform was used to evaluate a 300-compound library known for its anti-inflammatory potential. Among the screened compounds, Bicyclol emerged as a standout, exhibiting MyD88 binding and a significant reduction in LPS-stimulated pro-inflammatory factors production in mouse primary peritoneal macrophages. By targeting MyD88, Bicyclol disrupts the MyD88/TLR4 complex and MyD88 polymer formation, thereby mitigating the MAPKs and NF-κB signaling pathways. In vivo experiments further confirmed Bicyclol's efficacy, demonstrating alleviated ALI symptoms, decreased inflammatory cytokines level, and reduced inflammatory cells presence in lung tissues. These findings were associated with a decrease in mortality in LPS-challenged mice. Overall, Bicyclol represents a promising treatment option for ALI by specifically targeting MyD88 and limiting inflammatory responses.
资助项目	National Natural Science Foundation of Hebei[H2022206174];Hebei Provincial Education Department[BJK2024005];National Natural Science Foundation of China[82003644];Natural Science Foundation of Zhejiang Province[LZ22H300002];
出版者	Academic Press Inc.
ISSN	0041-008X
EISSN	1096-0333
卷号	487
DOI	10.1016/j.taap.2024.116958
页数	13
WOS类目	Pharmacology & Pharmacy ; Toxicology
WOS研究方向	Pharmacology & Pharmacy ; Toxicology
WOS记录号	WOS:001300124100001
收录类别	PUBMED ; SCOPUS ; SCIE
URL	查看原文
PubMed ID	38735591
SCOPUSEID	2-s2.0-85192877162
通讯作者地址	[Liu, Zhiguo]Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine,Vision and Brain Health),School of Pharmaceutical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,325000,China ; [Liang, Guang]School of Pharmaceutical Sciences,Hangzhou Medical College,Zhejiang,Hangzhou,310012,China
Scopus学科分类	Toxicology;Pharmacology
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/212861
专题	药学院（分析测试中心）其他_瓯江实验室
通讯作者	Liu, Zhiguo; Liang, Guang; Zhao, Weixin
作者单位	1.Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine,Vision and Brain Health),School of Pharmaceutical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,325000,China; 2.School of Pharmaceutical Sciences,Hangzhou Medical College,Zhejiang,Hangzhou,310012,China; 3.Department of Pharmacology,Hebei Medical University,Hebei,Shijiazhuang,050017,China
第一作者单位	药学院（分析测试中心）; 瓯江实验室
通讯作者单位	药学院（分析测试中心）; 瓯江实验室
第一作者的第一单位	药学院（分析测试中心）
推荐引用方式 GB/T 7714	Fu, Lili,Cheng, Linting,Lu, Junliang,et al. Bicyclol mitigates lipopolysaccharide-induced acute lung injury through myeloid differentiation factor 88 inhibition[J]. Toxicology and applied pharmacology,2024,487.
APA	Fu, Lili., Cheng, Linting., Lu, Junliang., Ye, Qianru., Shu, Cong., ... & Zhao, Weixin. (2024). Bicyclol mitigates lipopolysaccharide-induced acute lung injury through myeloid differentiation factor 88 inhibition. Toxicology and applied pharmacology, 487.
MLA	Fu, Lili,et al."Bicyclol mitigates lipopolysaccharide-induced acute lung injury through myeloid differentiation factor 88 inhibition".Toxicology and applied pharmacology 487(2024).